

R2 is Ala, Aib or Deg,

R3 is Gly, Aib, Deg, Dpg or Ac5c,

R4 is Leu or Ile

or a hydrolyzable carboxy protecting group; wherein at least one of R2 or R3 is an α,α -dialkylated amino acid; or a pharmaceutically acceptable salt of the peptide; wherein Aib is α -aminoisobutyric acid, Deg is α,α -diethyl glycine, Dpg is α,α -di-n-propyl glycine and Ac5c is 1-amino-cyclo pentane carboxylic acid.

12. (Amended) A composition comprising an effective amount of a peptide according to claim 1, and a pharmaceutically acceptable carrier.

13. (Amended) A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 1 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

14. (Amended) A method according to claim 13, further comprising administering a chemotherapeutic compound.

Please add the following claims:

21. A composition comprising an effective amount of a peptide according to claim 2, and a pharmaceutically acceptable carrier.

22. A composition comprising an effective amount of a peptide according to claim 3, and a pharmaceutically acceptable carrier.

23. A composition comprising an effective amount of a peptide according to claim 4, and a pharmaceutically acceptable carrier.

24. A composition comprising an effective amount of a peptide according to claim 5, and a pharmaceutically acceptable carrier.

25. A composition comprising an effective amount of a peptide according to claim 6, and a pharmaceutically acceptable carrier.
26. A composition comprising an effective amount of a peptide according to claim 7, and a pharmaceutically acceptable carrier.
27. A composition comprising an effective amount of a peptide according to claim 8, and a pharmaceutically acceptable carrier.
28. A composition comprising an effective amount of a peptide according to claim 9, and a pharmaceutically acceptable carrier.
29. A composition comprising an effective amount of a peptide according to claim 10, and a pharmaceutically acceptable carrier.
30. A composition comprising an effective amount of a peptide according to claim 11, and a pharmaceutically acceptable carrier.
31. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 2 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.
32. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 3 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.
33. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 4 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

34. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 5 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

35. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 6 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

36. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 7 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

37. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 8 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

38. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 9 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

39. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 10 to the mammal in need thereof, wherein the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

40. A method of treatment of cancer in a mammal which comprises administering an effective amount of a peptide according to claim 11 to the mammal in need thereof, wherein

the cancer is colon, lung, prostate, stomach, laryngeal, oral, breast, duodenum, ovarian or pancreatic or leukemia or glioblastoma.

41. A method according to claim 31, further comprising administering a chemotherapeutic compound.

42. A method according to claim 32, further comprising administering a chemotherapeutic compound.

43. A method according to claim 33, further comprising administering a chemotherapeutic compound.

44. A method according to claim 34, further comprising administering a chemotherapeutic compound.

45. A method according to claim 35, further comprising administering a chemotherapeutic compound.

46. A method according to claim 36, further comprising administering a chemotherapeutic compound.

47. A method according to claim 37, further comprising administering a chemotherapeutic compound.

48. A method according to claim 38, further comprising administering a chemotherapeutic compound.

49. A method according to claim 39, further comprising administering a chemotherapeutic compound.

50. A method according to claim 40, further comprising administering a chemotherapeutic compound.

51. A method according to claim 41, further comprising administering a chemotherapeutic compound.